Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01112956 · ClinicalTrials.gov registry record
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
A clinical trial, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- 2,500
- Enrollment target
NCT01112956: Completed study, sponsored by Centers for Disease Control and Prevention.
NCT01112956 is a clinical trial that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01112956 has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
The purposes of this study are: * To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); * To assess the sensitivity and specificity of the commerical assays using HSV-2 western blot as the "gold standard" in a diverse patient population; * To develop testing strategies and recommendations for screening asymptomatic populations for HSV-2.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-02 |
What the finished NCT01112956 record still lists
NCT01112956 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01112956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01112956 about?
NCT01112956 is a clinical study titled "Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2". The purposes of this study are: * To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); * To assess the sensitivity and specificity of the commerical assays using HSV-2 western blot as the "gold standard" in a diverse p...
What is the current status of trial NCT01112956?
This trial is currently completed. The enrollment target is 2,500 participants. The study started on 2009-07. Estimated completion is 2011-02.
Who is sponsoring clinical trial NCT01112956?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia